Biocon Ltd

(BIOCON)

Geojit Financial Services Recommends Accumulate on Biocon - 21 Nov, 2024

Geojit Financial Services has reiterated an 'Accumulate' rating on Biocon Ltd with a target price of Rs. 376. The company's revenue grew 3.7% YoY, driven by strong biosimilar sales, despite a decline in the generics segment. Biocon's growth prospects are bolstered by a VAI classification for its Biologics Park and early signs of recovery in its research services arm, Syngene.

Biocon Biologics Plans to Reduce Debt by $300 Million - 19 Nov, 2024

Biocon Biologics aims to reduce $300 million in acquisition debt within a year, following a recent refinancing of $1.1 billion. The company anticipates growth in its biosimilar and insulin markets, with plans to double insulin capacity in Malaysia. A positive USFDA inspection outcome could facilitate the launch of a new biosimilar in the US.

Biocon Group Focuses on Debt Reduction and Growth - 12 Nov, 2024

Biocon Group aims to reduce debt while navigating challenges in its generics business. Despite an 8% YoY revenue increase, generics revenue declined 8%. The company is optimistic about growth in the second half of the year, driven by investments in biosimilars and upcoming product launches.

Biocon Shares Surge After USFDA VAI Classification - 11 Nov, 2024

Biocon shares experienced significant gains after the USFDA classified its Bengaluru unit as Voluntary Action Indicated (VAI), confirming compliance with manufacturing standards. Despite a drop in Q2 FY25 profits, the positive regulatory outcome boosted investor confidence.

Biocon's Bengaluru Unit Receives USFDA VAI Classification - 10 Nov, 2024

Biocon's Park Site unit in Bengaluru has been classified as Voluntary Action Initiated (VAI) by the USFDA after an inspection in July 2024, potentially impacting stock performance.

Biocon Stock Shows Bullish Momentum and Targets - 08 Nov, 2024

Biocon's stock is exhibiting a bullish reversal pattern at Rs328, with upward targets set at Rs345 and Rs350. A stop loss at Rs320 is recommended to manage risk.

Biocon Ltd Reports Significant Profit Decline - 05 Nov, 2024

Biocon Ltd's profit plummeted over 84% to Rs 27.1 crore in Q2 FY2024, down from Rs 172.7 crore a year earlier. Revenue increased by 3.7% to Rs 3,590 crore, with biosimilar sales rising 4%.

Biocon Anticipates Growth Driven by Product Launches - 04 Nov, 2024

Biocon projects accelerated growth for H2FY25, supported by product launches and increased volume. The company maintains its guidance of $75 to $100 million for biologics and generics, with critical expansions and commissioning of facilities expected by fiscal year-end.

Biocon Reports Q2 Loss Amid Revenue Growth - 31 Oct, 2024

Biocon's Q2 FY25 results show a net loss of ₹16 crore, contrasting with last year's profit. Revenue increased by 3.7% to ₹3,590 crore, but operational challenges persist, particularly in the Generics segment. Analysts maintain mixed ratings, with a consensus to hold as the company navigates financial hurdles.

Biocon Reports Significant Profit Decline, FDA Classification - 30 Oct, 2024

Biocon's Q2 FY25 results show an 84.2% decline in net profit to ₹27.1 crore, missing estimates. Additionally, its Bengaluru facility received a voluntary action classification from the FDA.

Biocon Faces Challenges Amid Promising Biosimilar Results - 24 Oct, 2024

HSBC has downgraded Biocon's stock rating, citing litigation delays for its Yesafili biosimilar. Meanwhile, Biocon Biologics reported positive results for MYL-1701P, indicating safety and efficacy.